Health Canada approves two new mRNA vaccines from Moderna

Moderna, Inc. announced that Health Canada has granted authorization for mFLUSIVA®, an mRNA influenza vaccine, and mCOFLU®, a combined influenza and COVID-19 vaccine. This authorization applies to adults aged 50 and older. Canada is the first country to approve these innovative products designed to improve seasonal immunization.

mFLUSIVA and mCOFLU represent significant advances in the application of mRNA technology for the prevention of respiratory diseases. Clinical trials have demonstrated the relative efficacy and safety of the vaccines, although minor adverse reactions have been observed. These vaccines are currently undergoing regulatory review in other markets.

Moderna is committed to working with Canadian health authorities to facilitate the availability of these innovative vaccines that strengthen the resilience of health systems in the face of the ongoing challenges of flu seasons.